Complete Response for More than 4 Years following Neoadjuvant FOLFOX and Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for a Patient with Advanced Gastric Cancer with Extensive Peritoneal Carcinomatosis

Background: Peritoneal carcinomatosis is usually a terminal disease with short median survival in patients with gastric cancer. Systemic FOLFOX is one of the most used regimens in the first-line treatment of metastatic gastric cancer. However, there is scarce evidence that cytoreductive surgery (CRS...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2018-05, Vol.11 (2), p.305-310
Main Authors: Peixoto, Renata D’Alpino, de Sousa, Tercia Tarciane, Silva, Pedro Alexandre Ismael Amaral, de Meirelles, Luciana Rodrigues, Teixeira, Carlos Henrique Andrade
Format: Article
Language:English
Subjects:
Cancer therapies
Case Report
Case reports
Chemotherapy
Cytoreductive surgery
Gastric cancer
Intraperitoneal chemotherapy
Medical imaging
Medical prognosis
Multivariate analysis
Patients
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Peritoneal carcinomatosis is usually a terminal disease with short median survival in patients with gastric cancer. Systemic FOLFOX is one of the most used regimens in the first-line treatment of metastatic gastric cancer. However, there is scarce evidence that cytoreductive surgery (CRS) and intraperitoneal heated chemotherapy (HIPEC) improves oncological outcomes of patients with advanced gastric cancer. Methods: Herein we present a case of a young woman with advanced gastric cancer with omental and peritoneal metastases who achieved an excellent response after 6 months of FOLFOX followed by CRS and HIPEC. Results: A 53-year-old woman was diagnosed with advanced gastric carcinoma, with extensive omental caking and several peritoneal implants measuring 2 cm at the largest diameter. The patient received mFOLFOX6 for 6 months with excellent clinical and radiographic response. She was then submitted to a D2 total gastrectomy followed by CRS and HIPEC with mitomycin. The final pathology report showed a focal adenocarcinoma in the stomach measuring 0.4 mm with no residual tumor in the peritoneum (ypT1ypN0). The patient has been well and disease free for more than 4 years. Conclusion: While still controversial, CRS followed by HIPEC may be a curative therapeutic option for highly selected patients.
ISSN:1662-6575
1662-6575
DOI:10.1159/000488978